Prostate Cancer Clinical Trial

Genetic Investigation of Solid Tumors Cohort

Summary

The objective of this study is to obtain blood samples, solid tumor and/or benign hyperplasia samples to learn more about genetic differences that are linked to the formation of solid tumors.

View Full Description

Full Description

Recent studies in human genetics have discovered several intervals in the human genome containing inherited variants that are statistically associated with the propensity to develop solid tumors. Even though it has been firmly established that if an individual carries these DNA variants they have an increased chance of developing a solid tumor the underlying biological mechanisms for most of these associations are largely unknown.

In addition to inherited DNA variants that are associated with the development of solid tumors it is well established that during the development and growth of solid tumors the DNA in these cancer cells undergo somatic changes (mutations). These somatic DNA changes have been studied over the past decade and frequently are specific chromosomal translocations and amplifications associated with the development of particular solid tumors. In some instances, examining the chromosomal translocation and amplification has lead to the discovery of proteins contributing to solid tumor pathology.

the human 8q24 interval that has strong genetic associations with solid tumor development has also been noted as frequently amplified in solid tumors and serves as a predictor of poor survival in prostate cancers.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 18 years or older
Eligible to have their blood drawn
Be reliable, cooperative and willing to comply with all protocol-specified procedures
Able to understand and grant informed consent
Diagnosis of a solid tumor

Exclusion Criteria:

Has a significant chronic medical condition which would potentially confound interpretation of the individual's phenotype.
Treatment with any investigational agents or devices within thirty days preceding enrollment in the study.
Been administered or taken any CNS sedatives or depressants in the 12 hours prior to informed consent process

Study is for people with:

Prostate Cancer

Estimated Enrollment:

25

Study ID:

NCT01005225

Recruitment Status:

Completed

Sponsor:

Scripps Translational Science Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Scripps Health
San Diego California, 92037, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

25

Study ID:

NCT01005225

Recruitment Status:

Completed

Sponsor:


Scripps Translational Science Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider